cagrilintide results Our weight management program is growing-and we're excited to introduce a new peptide option to better support your results., is designed to help reduce hunger, increase fullness, and Cagrilintide medication for weight loss

Newer treatments for autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Certain populations may require more frequent maintenance

The second takeaway is that this underscores a point that we make frequently in these blogs- that there is a real link between the gut and the brain, and that injury or dysbiosis in one can lead to problems with the other

Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained